State of Wisconsin Investment Board bought a new stake in Genomic Health, Inc. (NASDAQ:GHDX) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 15,000 shares of the medical research company’s stock, valued at approximately $488,000.
Several other large investors have also made changes to their positions in GHDX. Dubuque Bank & Trust Co. raised its holdings in shares of Genomic Health by 8.4% in the second quarter. Dubuque Bank & Trust Co. now owns 4,897 shares of the medical research company’s stock valued at $159,000 after buying an additional 379 shares during the last quarter. Legal & General Group Plc raised its holdings in shares of Genomic Health by 48.7% in the first quarter. Legal & General Group Plc now owns 6,222 shares of the medical research company’s stock valued at $196,000 after buying an additional 2,038 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in shares of Genomic Health in the first quarter valued at about $218,000. Envestnet Asset Management Inc. raised its holdings in shares of Genomic Health by 13.6% in the first quarter. Envestnet Asset Management Inc. now owns 8,282 shares of the medical research company’s stock valued at $259,000 after buying an additional 993 shares during the last quarter. Finally, Airain ltd purchased a new stake in shares of Genomic Health in the first quarter valued at about $285,000. 88.91% of the stock is owned by institutional investors and hedge funds.
Genomic Health, Inc. (GHDX) opened at 31.86 on Wednesday. The firm’s market capitalization is $1.10 billion. Genomic Health, Inc. has a 52 week low of $26.37 and a 52 week high of $33.97. The stock’s 50 day moving average is $31.06 and its 200-day moving average is $31.59.
Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings data on Tuesday, August 1st. The medical research company reported ($0.08) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.02). The firm had revenue of $85.50 million during the quarter, compared to the consensus estimate of $86.08 million. Genomic Health had a negative net margin of 1.50% and a negative return on equity of 4.33%. The company’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.18) earnings per share. On average, equities research analysts expect that Genomic Health, Inc. will post ($0.01) EPS for the current year.
GHDX has been the subject of a number of research reports. Cowen and Company reaffirmed a “hold” rating and issued a $34.00 target price on shares of Genomic Health in a report on Friday, September 1st. BidaskClub raised shares of Genomic Health from a “sell” rating to a “hold” rating in a report on Saturday, August 26th. Canaccord Genuity reduced their target price on shares of Genomic Health from $36.00 to $35.00 and set a “buy” rating for the company in a report on Tuesday, August 15th. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $31.00 target price on shares of Genomic Health in a report on Thursday, August 3rd. Finally, Jefferies Group LLC reaffirmed a “hold” rating and issued a $33.00 target price on shares of Genomic Health in a report on Monday, June 12th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $32.00.
In related news, CEO Kimberly J. Popovits sold 1,468 shares of Genomic Health stock in a transaction dated Wednesday, July 5th. The shares were sold at an average price of $32.67, for a total value of $47,959.56. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO G Bradley Cole sold 5,000 shares of Genomic Health stock in a transaction dated Tuesday, July 11th. The shares were sold at an average price of $32.53, for a total transaction of $162,650.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 37,642 shares of company stock worth $1,195,131. 46.20% of the stock is currently owned by insiders.
About Genomic Health
Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.